Focused Alpha LLC Purchases New Position in United Therapeutics Corporation $UTHR

Focused Alpha LLC acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 992 shares of the biotechnology company’s stock, valued at approximately $538,000.

Other institutional investors also recently bought and sold shares of the company. Callan Family Office LLC purchased a new stake in shares of United Therapeutics during the second quarter valued at about $1,217,000. Andra AP fonden grew its position in shares of United Therapeutics by 33.5% in the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after buying an additional 8,760 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of United Therapeutics during the 2nd quarter worth approximately $3,359,000. Partners Capital Investment Group LLP bought a new position in shares of United Therapeutics during the 2nd quarter worth approximately $1,691,000. Finally, Hsbc Holdings PLC lifted its position in United Therapeutics by 6.6% during the second quarter. Hsbc Holdings PLC now owns 127,125 shares of the biotechnology company’s stock valued at $68,899,000 after acquiring an additional 7,890 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total value of $4,902,570.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 392,028 shares of company stock worth $202,907,986 over the last three months. Company insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on UTHR. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Morgan Stanley boosted their target price on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. UBS Group set a $725.00 price target on United Therapeutics in a report on Monday. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $650.00.

United Therapeutics Stock Up 1.9%

United Therapeutics stock opened at $543.15 on Tuesday. The stock has a 50-day moving average price of $513.91 and a 200 day moving average price of $539.71. The company has a market capitalization of $23.30 billion, a price-to-earnings ratio of 19.43, a price-to-earnings-growth ratio of 3.81 and a beta of 0.49. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm posted $6.41 EPS. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.